Novo Nordisk To Restrict Initial Wegovy Sales In China Amid High Demand [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
China's National Health Commission survey revealed over half of its 1.4 billion population is overweight or obese. Also Read: Novo Nordisk's Older Generation Weight-Loss Drug Saxenda Associated With Decreased Bone Mass Density, Study Shows Maziar Mike Doustdar , Novo Nordisk's chief of international operations, stated the company aims to launch Wegovy in China soon, prioritizing continuous supply without affecting availability elsewhere. China's health authorities recently approved Wegovy, offering a new weight loss option in a market where Novo Nordisk's diabetes drug, Ozempic, has been used off-label to shed weight As urbanization drives obesity rates, China's market for GLP-1 drugs like Wegovy could reach 40 billion yuan ($5.5 billion) by 2030, Bloomberg notes, citing HSBC analysis. However, Novo Nordisk's patent on semaglutide, Wegovy's active ingredient, expires in 2026, with Hangzhou Jiuyuan Gene Engineering Co. and Livzon Pharmaceutical Group Inc. already seeking to
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Fixing the Broken Rung: Better approaches to promotion and talent development [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Pharma Stock Roundup: FDA's CRL to MRK & ABBV, Phase III Study Failures for NVO, AZN [Yahoo! Finance]Yahoo! Finance
- Keep faith in China, Li Qiang tells business at ‘Summer Davos' [Yahoo! Finance]Yahoo! Finance
- SNIPR Biome receives funding for the development of CRISPR-medicines to improve Environmental Enteric Dysfunction (EED) in pregnant women [Yahoo! Finance]Yahoo! Finance
- Fake Ozempic and Wegovy are flooding the market. Here are 4 steps to avoid dangerous counterfeit weight loss drugs [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 5/3/24 - Beat
NVO
Sec Filings
- 6/26/24 - Form 6-K
- 6/24/24 - Form 6-K
- 6/21/24 - Form 11-K
- NVO's page on the SEC website